Hoechst Marion Roussel Amaryl Sales Reach $62 Mil. In Second Quarter
Executive Summary
Worldwide sales of Hoechst Marion Roussel's Amaryl sulfonylurea treatment for type 2 diabetes increased by 77% in the second quarter to $62 mil. (EURO 58 mil.), the company reported in an Aug. 4 statement on financial results.